



CIN No. L24232PB1983PLC005426

D.L. No. 1800-OSP, 1804-B

GST No. 03AAACK6458M1ZB

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LTD.

Regd. Office: 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Global Address: N: 31.713874, L: 74.930479

Phone : 91-8558820862 (Accounts)

: 91-8558820863 (Admin.)

: 91-9915743720 (Exports)

M.D. Mobile : 91-9814071215, 9814052314

E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com

To
The BSE Limited
Department of Corporate Services,
P.J. Towers, Dalal Street,
Mumbai-400001

Date: 24 July 2026

Subject: Kwality Pharmaceuticals Ltd receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab

Dear Sir/Madam,

Kwality Pharmaceuticals Limited has achieved a significant milestone in its biologics development journey after receiving permission from the **Central Drugs Standard Control Organization (CDSCO)** to manufacture **pilot batches of Pembroluzimab for preclinical studies**.

The approval follows a comprehensive review of the product's development data submitted by the Company's R&D team. Based on the data evaluated, CDSCO has granted permission to proceed with pilot-scale manufacturing for the generation of preclinical batches, marking the product's transition from the research and development stage to Pre-Clinical stage.

KPL aims to be among the first wave of generic manufacturers to launch Pembroluzimab following the expiry of the reference product's patent, subject to successful development and the necessary regulatory approvals.

For Kwality Pharmaceuticals Ltd.

Ramesh Kumar
Managing Director
DIN: 00462656

